Unlock more results with a Fundz subscription — Get started today!
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Trefoil Therapeutics Announces Third Tranche Of $28 Million Series A Financing Based On Achievement Of Clinical Trial Objectives
Trefoil Therapeutics Announces Third Tranche Of $28 Million Series A Financing Based On Achievement Of Clinical Trial Objectives
12/01/21, 2:00 PM
Location
san diegoMoney raised
$28 million
Round Type
series a
Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A financing to support the development of its engineered FGF-1, TTHX1114 products for the regenerative treatment of corneal diseases. This funding allows Trefoil to expand the STORM clinical program and initiate a clinical trial of the topical formulation.
Company Info
Location
san diego, california, united states
Additional Info
Trefoil Therapeutics is a clinical stage biotechnology company focused on leveraging its engineered FGF-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders. Trefoil’s lead product candidate is TTHX1114, an engineered form of naturally occurring FGF-1 designed to stimulate corneal endothelial cell proliferation and migration, thereby reversing vision loss caused by CED. The technology underlying Trefoil’s platform was developed by co-founder Michael Blaber, Ph.D., and is licensed from Florida State University. Learn more at www.trefoiltherapeutics.com.
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.